Due to the importance of the EGFR in the pathogenesis of a variety of epithelial cancers including SCC and NSCLC, clinically relevant inhibitors of this receptor have been developed but have shown only limited activity as single agents in NSCLC patients [10], [51]. Here, EGFR is linked to non-small cell lung carcinoma.